Integrating single-cell and bulk RNA sequencing with ML algorithms identified MYBL2 as a candidate transcriptomic biomarker for diagnosing laryngeal squamous cell carcinoma (LSCC)
5 affiliations
- 1Department of Cellular and Molecular Biology, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
- 2Department of Biological Sciences, Bowling Green State University, Bowling Green, OH, United States
- 3Department of Electrical Engineering, Faculty of Technology and Engineering, Central Tehran Branch, Islamic Azad University, Tehran, Iran
- 4Pediatric Cell and Gene Therapy Research Center, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran
- 5Department of Obstetrics & Gynecology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, 43400, Malaysia
Abstract
Laryngeal squamous cell carcinoma (LSCC) poses significant clinical challenges due to pronounced tumor heterogeneity. To identify robust, consistent biomarkers across cohorts, we integrated bulk RNA sequencing (RNA-seq) data from GSE127165 and GSE142083 and validated candidate biomarkers in the external cohort GSE13060. Candidate gene prioritization incorporated differentially expressed genes, weighted gene co-expression network analysis (WGCNA) results, and markers of malignant epithelial cells exhibiting high copy number variation (High-CNV) derived from single-cell RNA sequencing (scRNA-seq) (GSE206332). Additional analyses included functional enrichment, immune association (adjusted for tumor purity), quasi-temporal analysis, and CellChat inference to elucidate the biological roles of top genes. The integrated approach identified 254 differentially expressed genes (DEGs), comprising 86 upregulated and 168 downregulated genes. WGCNA revealed a tumor-associated module containing 870 genes. Intersecting these findings with high-CNV malignant epithelial markers reduced the candidate pool to 16 genes, and LASSO regression retained five key features: MYBL2, KRT17, UCHL1, PTHLH, and ODC1. Among these, MYBL2 demonstrated the strongest and most consistent performance. MYBL2 was further associated with proliferative programs, including E2F targets, the G2/M checkpoint, DNA repair, and MYC targets. Gene signatures from these subclusters were enriched in bulk tumors and positively correlated with MYBL2 expression in independent cohorts. The results also indicate that MYBL2-high malignant epithelial states are linked to distinct connectivity patterns within the tumor microenvironment.
Related
- Key genes and pathways of pulmonary hypertension identified by integrating bulk and single-cell RNA sequencing
- Juvenile Huntington Disease With Cerebellar‐Predominant Atrophy Identified by Genome Sequencing
- Rare missense variants identified by whole-genome sequencing in men with oligoasthenoteratozoospermia: An experimental study
- Microbial cell-free DNA sequencing for diagnosing lung infections in immunocompromised patients.
- Molecular overlap between primary immune thrombocytopenia and inherited platelet disorders: A pediatric case report with a novel heterozygous ITGB3 variant identified by next-generation sequencing
BibTeX
@article{mehrabi2026integrating,
title = {{Integrating single-cell and bulk RNA sequencing with ML algorithms identified MYBL2 as a candidate transcriptomic biomarker for diagnosing laryngeal squamous cell carcinoma (LSCC)}},
author = {Tahmineh Mehrabi and Marzie Isavi and Ali Gholami and Amir Ali Hamidieh and Roozbeh Heidarzadeh-Pilehrood},
journal = {Translational Oncology},
year = {2026},
month = nov,
doi = {10.1016/j.tranon.2026.103095},
url = {https://doi.org/10.1016/j.tranon.2026.103095},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Integrating single-cell and bulk RNA sequencing with ML algorithms identified MYBL2 as a candidate transcriptomic biomarker for diagnosing laryngeal squamous cell carcinoma (LSCC)
AU - Tahmineh Mehrabi
AU - Marzie Isavi
AU - Ali Gholami
AU - Amir Ali Hamidieh
AU - Roozbeh Heidarzadeh-Pilehrood
PY - 2026
DA - 2026/11/01
JO - Translational Oncology
DO - 10.1016/j.tranon.2026.103095
UR - https://doi.org/10.1016/j.tranon.2026.103095
AB - Laryngeal squamous cell carcinoma (LSCC) poses significant clinical challenges due to pronounced tumor heterogeneity. To identify robust, consistent biomarkers across cohorts, we integrated bulk RNA sequencing (RNA-seq) data from GSE127165 and GSE142083 and validated candidate biomarkers in the external cohort GSE13060. Candidate gene prioritization incorporated differentially expressed genes, weighted gene co-expression network analysis (WGCNA) results, and markers of malignant epithelial cells exhibiting high copy number variation (High-CNV) derived from single-cell RNA sequencing (scRNA-seq) (GSE206332). Additional analyses included functional enrichment, immune association (adjusted for tumor purity), quasi-temporal analysis, and CellChat inference to elucidate the biological roles of top genes. The integrated approach identified 254 differentially expressed genes (DEGs), comprising 86 upregulated and 168 downregulated genes. WGCNA revealed a tumor-associated module containing 870 genes. Intersecting these findings with high-CNV malignant epithelial markers reduced the candidate pool to 16 genes, and LASSO regression retained five key features: MYBL2, KRT17, UCHL1, PTHLH, and ODC1. Among these, MYBL2 demonstrated the strongest and most consistent performance. MYBL2 was further associated with proliferative programs, including E2F targets, the G2/M checkpoint, DNA repair, and MYC targets. Gene signatures from these subclusters were enriched in bulk tumors and positively correlated with MYBL2 expression in independent cohorts. The results also indicate that MYBL2-high malignant epithelial states are linked to distinct connectivity patterns within the tumor microenvironment.
SN - 1936-5233
ER -